Logo image of RLAY

RELAY THERAPEUTICS INC (RLAY) Stock Fundamental Analysis

NASDAQ:RLAY - Nasdaq - US75943R1023 - Common Stock - Currency: USD

3.92  -0.17 (-4.16%)

After market: 3.93 +0.01 (+0.26%)

Fundamental Rating

3

RLAY gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. While RLAY has a great health rating, there are worries on its profitability. RLAY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RLAY has reported negative net income.
In the past year RLAY has reported a negative cash flow from operations.
In the past 5 years RLAY always reported negative net income.
In the past 5 years RLAY always reported negative operating cash flow.
RLAY Yearly Net Income VS EBIT VS OCF VS FCFRLAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

RLAY has a Return On Assets of -64.90%. This is in the lower half of the industry: RLAY underperforms 62.52% of its industry peers.
RLAY has a Return On Equity of -71.96%. This is comparable to the rest of the industry: RLAY outperforms 55.24% of its industry peers.
Industry RankSector Rank
ROA -64.9%
ROE -71.96%
ROIC N/A
ROA(3y)-34.34%
ROA(5y)-30.19%
ROE(3y)-38.86%
ROE(5y)-33.56%
ROIC(3y)N/A
ROIC(5y)N/A
RLAY Yearly ROA, ROE, ROICRLAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

RLAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLAY Yearly Profit, Operating, Gross MarginsRLAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K

More info and screens

7

2. Health

2.1 Basic Checks

RLAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RLAY has more shares outstanding
Compared to 5 years ago, RLAY has more shares outstanding
RLAY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLAY Yearly Shares OutstandingRLAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
RLAY Yearly Total Debt VS Total AssetsRLAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

RLAY has an Altman-Z score of 0.75. This is a bad value and indicates that RLAY is not financially healthy and even has some risk of bankruptcy.
RLAY has a better Altman-Z score (0.75) than 65.19% of its industry peers.
There is no outstanding debt for RLAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.75
ROIC/WACCN/A
WACC9.44%
RLAY Yearly LT Debt VS Equity VS FCFRLAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M 800M

2.3 Liquidity

RLAY has a Current Ratio of 18.42. This indicates that RLAY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 18.42, RLAY belongs to the top of the industry, outperforming 93.43% of the companies in the same industry.
A Quick Ratio of 18.42 indicates that RLAY has no problem at all paying its short term obligations.
RLAY has a Quick ratio of 18.42. This is amongst the best in the industry. RLAY outperforms 93.43% of its industry peers.
Industry RankSector Rank
Current Ratio 18.42
Quick Ratio 18.42
RLAY Yearly Current Assets VS Current LiabilitesRLAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.97% over the past year.
Looking at the last year, RLAY shows a very strong growth in Revenue. The Revenue has grown by 37.80%.
Measured over the past years, RLAY shows a very negative growth in Revenue. The Revenue has been decreasing by -32.39% on average per year.
EPS 1Y (TTM)2.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)37.8%
Revenue growth 3Y-32.39%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 6.76% on average over the next years.
Based on estimates for the next years, RLAY will show a very strong growth in Revenue. The Revenue will grow by 38.84% on average per year.
EPS Next Y8.27%
EPS Next 2Y1.95%
EPS Next 3Y2.24%
EPS Next 5Y6.76%
Revenue Next Year-39.68%
Revenue Next 2Y-63.06%
Revenue Next 3Y-4.15%
Revenue Next 5Y38.84%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RLAY Yearly Revenue VS EstimatesRLAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
RLAY Yearly EPS VS EstimatesRLAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLAY. In the last year negative earnings were reported.
Also next year RLAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLAY Price Earnings VS Forward Price EarningsRLAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLAY Per share dataRLAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.95%
EPS Next 3Y2.24%

More info and screens

0

5. Dividend

5.1 Amount

RLAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELAY THERAPEUTICS INC

NASDAQ:RLAY (2/21/2025, 8:00:01 PM)

After market: 3.93 +0.01 (+0.26%)

3.92

-0.17 (-4.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-26 2025-02-26/amc
Inst Owners82.86%
Inst Owner Change4.18%
Ins Owners1.92%
Ins Owner Change2.45%
Market Cap656.13M
Analysts86.32
Price Target21.93 (459.44%)
Short Float %11.6%
Short Ratio6.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.61%
Min EPS beat(2)7.69%
Max EPS beat(2)19.53%
EPS beat(4)4
Avg EPS beat(4)12.7%
Min EPS beat(4)7.69%
Max EPS beat(4)19.53%
EPS beat(8)7
Avg EPS beat(8)12.61%
EPS beat(12)8
Avg EPS beat(12)7.42%
EPS beat(16)10
Avg EPS beat(16)3.04%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)3053.38%
Min Revenue beat(4)-100%
Max Revenue beat(4)12513.5%
Revenue beat(8)3
Avg Revenue beat(8)2332.96%
Revenue beat(12)4
Avg Revenue beat(12)1547.02%
Revenue beat(16)6
Avg Revenue beat(16)1189.6%
PT rev (1m)0%
PT rev (3m)-3.59%
EPS NQ rev (1m)2.95%
EPS NQ rev (3m)9.47%
EPS NY rev (1m)0%
EPS NY rev (3m)5.34%
Revenue NQ rev (1m)6740.36%
Revenue NQ rev (3m)7500.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)53.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.45
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-2.61
EYN/A
EPS(NY)-2.69
Fwd EYN/A
FCF(TTM)-1.69
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0.21
BVpS5.01
TBVpS5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.9%
ROE -71.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.34%
ROA(5y)-30.19%
ROE(3y)-38.86%
ROE(5y)-33.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.74%
Cap/Sales 6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.42
Quick Ratio 18.42
Altman-Z 0.75
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)128.66%
Cap/Depr(5y)144.21%
Cap/Sales(3y)262.4%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y8.27%
EPS Next 2Y1.95%
EPS Next 3Y2.24%
EPS Next 5Y6.76%
Revenue 1Y (TTM)37.8%
Revenue growth 3Y-32.39%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-39.68%
Revenue Next 2Y-63.06%
Revenue Next 3Y-4.15%
Revenue Next 5Y38.84%
EBIT growth 1Y-86.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.79%
EBIT Next 3Y-7.78%
EBIT Next 5Y0.18%
FCF growth 1Y-28.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.2%
OCF growth 3YN/A
OCF growth 5YN/A